Vimarsana
Biggest News Aggregation in the World

Page 3 - Image Analysis Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Image Analysis Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Image Analysis Group Today - Breaking & Trending Today

Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients - Vimarsana News

Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients

Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients ACCESSWIRE WALNUT CREEK, CA and LONDON, UK / ACCESSWIRE / May 3, 2021 / Vivacitas Oncology, Inc. (' Vivacitas' or the ' Company'), a clinical stage biopharmaceutical company focused on tough to treat cancers, and Image Analysis Group ('IAG'), a leading global medical imaging company, are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67, a third generation Camptothecin, in patients ...

Baystreet.ca - Some of the Top Pharmaceutical Companies to Watch in New Year 2021 - Vimarsana News

Baystreet.ca - Some of the Top Pharmaceutical Companies to Watch in New Year 2021

Some of the Top Pharmaceutical Companies to Watch in New Year 2021 “Glioblastoma is the most common and aggressive cancerous brain tumour in adults due to its resistance to therapy. Treatment usually involves surgery, followed by chemotherapy and radiation therapy. Despite these intensive efforts, in most cases tumour cells regrow after treatment and the cancer recurs,” reports Science Daily. However, there may be a treatment option with the development of Berubicin, an anthracycline anticancer drug used for the treatment of malignant gliomas, as noted by Targeted Oncology. As re...